The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma
Clinical trial NCT03295240 · COMPLETED
Trial details
- NCT number
- NCT03295240
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Status
- COMPLETED
- Phase
- Early Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2017-09-20
- Primary completion
- 2024-01-22
- Enrollment
- 10
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.